Depression is one of the most debilitating neuropsychiatric disorders. Most of the current antidepressants have long remission time and low recovery rate. This study explores the impact of ketamine on neuronal and astroglial metabolic activity in prefrontal cortex in a social defeat (SD) model of depression. C57BL/6 mice were subjected to a social defeat paradigm for 5 min a day for 10 consecutive days. Ketamine (10 mg/kg, intraperitoneal) was administered to mice for two consecutive days following the last defeat stress. Mice were infused with [1,[6][7][8][9][10][11][12][13] Ac(Ox) , cerebral metabolic rate of acetate oxidation; CMR Glc , cerebral metabolic rate of glucose oxidation; EAAT2, excitatory amino acid transporter 2; GABA, c-amino butyric
neuronal and astroglial metabolic activity, respectively, together with proton-observed carbon-edited nuclear magnetic resonance spectroscopy in prefrontal cortex tissue extract. The 13 C labeling of amino acids from glucose and acetate was decreased in SD mice. Ketamine treatment in SD mice restored sucrose preference, social interaction and immobility time to control values. Acute subanesthetic ketamine restored the 13 C labeling of brain amino acids from glucose as well as acetate in SD mice to the respective control values, suggesting that rates of neuronal and astroglial tricarboxylic acid (TCA) cycle and neurotransmitter cycling were re-established to normal levels. The finding of improved energy metabolism in SD mice suggests that fast anti-depressant action of ketamine is linked with improved neurotransmitter cycling. Keywords: 13 C nuclear magnetic resonance spectroscopy, camino butyric acid, glutamate, glutamine, neuron-glia interaction, neurotransmission. J. Neurochem. (2018) 146, 722--734.
Major depressive disorder (MDD) is a neuropsychiatric disorder, and a leading cause of disability worldwide (Belmaker and Agam 2008; Ferrari et al. 2013) . Anhedonia, the feeling of guilt, suicidal ideation and social avoidance are common symptoms of MDD. Histological analysis of postmortem brain tissue taken from individuals with MDD has shown reductions in cortical thickness, neuronal size and neuronal and glial densities in the upper (II-IV) cortical layers of the rostral orbitofrontal region (Ongur et al. 1998; Rajkowska et al. 1999) . The evidence of a reduction in glial population was further established by a study wherein an injection of L-alpha aminoadipic acid, a glial toxin, in the prefrontal cortex (PFC) induced a depression-like phenotype in mice (Banasr and Duman 2008) . Imaging studies have indicated a reduction in glucose metabolism and blood flow in PFC of depressed patients (Videbech 2000) . The metabolic analysis in social defeat (SD) model of depression has shown reduced 13 C labeling of glutamate-C4, glutamate-C3 and c-amino butyric acid (GABA)-C2 in the PFC from [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose indicating reduced excitatory and inhibitory neuronal activity and neurotransmitter cycling in depression (Veeraiah et al. 2014) . Results from pre-clinical studies have provided evidence that stress reduces dendrite length and neuronal number, thereby decreasing synaptic density (Li et al. 2011) . PFC is central to the reward pathway and important for intelligence, decision-making and executive functions (Kesner and Churchwell 2011) . There is also an evidence of morphometric changes in PFC from postmortem, and imaging studies in depressed subjects (Grieve et al. 2013) . Together, these findings suggest an involvement of neuronal dysfunction, especially in PFC in the pathophysiology of MDD.
Most of the current antidepressants which are developed based on monoamine receptor targets (Elhwuegi 2004) suffer from the disadvantage of low recovery rate and long remission time (Gaynes et al. 2009 ). Moreover, many clinically depressed individuals do not respond to these antidepressants. Hence, there is an urgent need for effective and fast acting antidepressant(s). In this regard, N-methyl-Daspartate (NMDA) receptor antagonists have shown promising results (Trullas and Skolnick 1990; Layer et al. 1995) . Ketamine, an NMDA receptor antagonist, exhibits fast antidepressant properties at subanesthetic doses, and is effective in individuals with treatment-resistant depression (Berman et al. 2000; Murrough et al. 2013 ). Recent molecular studies in rodents show that ketamine's antidepressant effects involve activation of the mammalian target of rapamycin pathway and synaptogenesis (Li et al. 2010; Duman et al. 2012) . Administration of subanesthetic doses of ketamine results in a transient release of glutamate into extracellular fluid (Moghaddam et al. 1997) , and transient increase in glutamate-glutamine cycling (Chowdhury et al. 2017) in rat PFC. However, the impact of ketamine on neuronal and astroglial energetics, and neurotransmitter cycling in depression is not clear.
Glutamate and GABA are major excitatory and inhibitory neurotransmitters in the central nervous system, respectively. Alterations in glutamatergic and GABAergic neuronal activity have been shown in several neurological and psychiatric disorders, including depression (Bagga et al. 2013; Abdallah et al. 2014; Nilsen et al. 2014; Veeraiah et al. 2014; Patel et al. 2018) . Therefore, targeting the glutamatergic system may be a good strategy for the treatment of depression (Sanacora et al. 2008; Murrough et al. 2017) . In this study, we have assessed the effect of ketamine on neurometabolic activity in a SD mouse model of depression using proton-observed carbon-edited nuclear magnetic resonance ( 1 H-[ 13 C]-NMR) spectroscopy in conjunction with an infusion of either [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose or [2- 13 C]acetate. Our data indicated that glutamatergic, GABAergic and astroglial metabolic activity were reduced in SD mice. Most interestingly, our findings indicate that acute ketamine administration to SD mice restored behavior and neuronal-astroglial metabolic activity.
Materials and methods

Animals
All procedures with animals were approved by the Institutional Animal Ethics Committee (Protocol No. IAEC#46/2013), CCMB, Hyderabad, and conducted in accordance with the guidelines established by the Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Environment and Forests, Government of India. The study was not pre-registered for preclinical study. ARRIVE guidelines were followed in the preparation of the manuscript. Eight weeks old C57BL/6J male mice (Stock ID: 000664, RRID:IMSR_JAX:000664; Jackson Laboratory, Bar Habor, ME, USA) with weight in the range of 22-26 g were housed in a room maintained at 23-25°C, and relative humidity of 50%-70% with 12-h/12-h light/dark cycle that was turned ON and OFF at 6:00 am and 6:00 pm, respectively, in the CCMB Animal House Facility with free access to food and water. Mice were divided into two major groups: SD (n = 25) and control (n = 24) (Fig. 1) . For SD group, each mouse was housed in individual cage, Fig. 1 Schematic representation of the timeline of different treatments in mice. Mice were subjected to 10 days of social defeat followed by behavioral analysis and saline (SD + NS, n = 12) or ketamine (SD + Ket, n = 13) treatment (10 mg/kg, intraperitoneal). Control mice were also administered either saline (Cont + NS, n = 11) or ketamine (Cont + Ket, n = 13). Metabolic analysis was carried out on 16th day.
whereas two mice per cage were homed in controls. Following 10 days of SD paradigm, the mice were subdivided into the following groups for either ketamine or normal saline (NS; 0.9% NaCl) treatment: Group (i) Control + NS (n = 11); Group (ii) Control + Ketamine (Ket, n = 13); Group (iii) SD + NS (n = 12); Group (iv) SD + Ket (n = 13) (Fig. 1) . The groups of mice were further subdivided, and infused either with 13 C-labeled glucose or acetate to evaluate neuronal and astroglial metabolic activity. A similar protocol was used in our previous study, which indicated that n = 7 is sufficient to discriminate SD mice (in terms of behavioral and metabolic rates) from age-matched controls (Veeraiah et al. 2014) ; thus, a sample size calculation was not performed for this study. Although mice were not specifically randomized, we insured that the variation in body weight was similar among groups. Laboratory investigators were not blinded to the identity of the samples prepared during the study. As described below, all mice found susceptible to SD stress upon behavioral testing, and all samples prepared from these mice were included in the final analysis, and no samples or data were excluded. All the measurements, which include behavioral and metabolic assessment, were carried out between 10:00 am and 5:00 pm.
SD paradigm
Retired breeder male CD1 mice were used as resident aggressors in the SD paradigm (Veeraiah et al. 2014) . In brief, an experimental C57BL/6 mouse was introduced in the home cage of an aggressive CD1 mouse. Following 5 min of exposure of the test C57BL/6 mouse to the aggressor, the animals were physically separated while maintaining sensory contact by use of a perforated Plexiglas barrier that divides the cage into two halves. The SD paradigm was repeated for 10 consecutive days using a different CD1 aggressor mouse on each day (Veeraiah et al. 2014) . Control mice were housed in pairs for preventing the effect of stress caused by isolation. When appropriate, in the case of injury, Himax ointment was applied to prevent infection and promote healing of the wound.
Ketamine treatment
At the end of the SD paradigm, animals of Group (ii) and (iv) were administered ketamine (Ketamil, Ilium; Troy Laboratories PTY Limited, Glendenning, NSW, Australia) intraperitoneally (10 mg/ kg) on day 12 and 13 during 10:00 am -12:00 noon, whereas those in Group (i) and (iii) were given NS (0.9% NaCl) intraperitoneally at same time (Fig. 1) . A recent study of cerebral metabolism in awake rats indicated ketamine (10 and 30 mg/kg) has a maximum change in the labeling of glutamate-C4, GABA-C2 and glutamine-C4 (Chowdhury et al. 2017) . Moreover, administration of S-ketamine (3 mg/kg, i.p.), one of the enantiomers of ketamine, produced timedependent changes in the level of hippocampal metabolites in C57BL/6 mice (Weckmann et al. 2014) .
Behavioral analysis
Exposure of mice to the SD paradigm results in the development of a depression-like phenotype. The following behavioral tests were conducted:
Sucrose preference
The mice were acclimatized to the provision of choice between two water bottles before commencement of the SD paradigm, for which two identical water bottles were provided in each cage for the first 2 days, and were replaced with 2% sucrose solution for the next 2 days. During the sucrose preference test period (5 th day onward), one of the sucrose bottles was replaced with a water bottle (Strekalova et al. 2004) . The consumption of fluid in each bottle was monitored daily. The percentage of sucrose solution consumed (a measure of anhedonia) was calculated as follows:
Sucrose Preference ¼ 100 Â Volume of Sucrose Solution Consumed Total Volume of Liquid Consumed ;
The total volume represents the sum of sucrose and water. Mice showing sucrose preference scores less than 80% were considered behaviorally depressed, and those having more than 80% were considered resilient, and excluded from the study.
Social interaction
In this analysis, mice were allowed to explore freely an arena, which is virtually divided into different zones such as interaction zone, corner zone and target zone. The time spent by the test mouse in the interaction zone was monitored in the presence and absence of an aggressor target CD1 mouse using tracking software (Ethovision Noldus Ver 3.1, RRID:SCR_004074, Wageningen, the Netherlands) (Tsankova et al. 2006) . The social interaction (SI) score was calculated as a percentage ratio of the time spent by mice in the interaction zone with and without an aggressor mouse in the target zone. Mice subjected to SD having an SI score < 100%, and reduced preference for sucrose, were considered depressed. The rest of the animals that showed higher sucrose preference (> 80%) and SI ratio (> 100%) during the first behavioral screening were considered resilient, and were excluded from the study. In addition, control mice, which showed lower sucrose preference (< 80%) and SI ratio (< 100%) were excluded from the study.
Forced swim test
In brief, mice were placed in a ten-liter glass beaker filled with water having temperature 23 AE 2°C upto 2/3 rd volume, and allowed to swim freely for 5 min (Slattery and Cryan 2012) . The swimming behavior of mice was monitored using video tracking (Ethovision Noldus Ver 3.1). The time spent by mice in an immobile state with both front limbs stationary, which is a measure of behavioral despair, was measured by analysis of the video recordings.
Infusion of [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose and [2-
For metabolic analysis, mice fasted for 6 h were anesthetized with urethane (1.5 g/kg, intraperitoneal), and core body temperature was maintained at 37°C using a heating pad. The respiration rate of animals was monitored using the Biopac data acquisition system (RRID:SCR_014829, Santa Barbara, CA, USA). After 45 min of anesthesia, [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose (Fitzpatrick et al. 1990) or [2-
13
C] acetate (Patel et al. 2017) was administered intravenously using bolus-variable rate infusions for 10 and 15 min, respectively. The [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose (Catalogue No. CLM-2717-PK, 99 atom %; Cambridge Isotope Laboratories Inc., Andover, MA, USA) (0.225 mol/L) was dissolved in deionized water, and delivered as a bolus (1013 lmol/kg) for the first 15 s, followed by an exponentially decreasing infusion rate every 30 s for the next 8 min, whereupon the infusion rate was constant (51 lmol/kg/min) until in situ brain freezing at 10 min. [2- (1 mol/L) and unlabeled glucose (0.225 mol/L), dissolved in deionized water and pH adjusted to 7.0, were administered to mice as a bolus -variable rate infusion of 3.0 mmol/kg/min (0-15 s), 0.60 mmol/kg/min (15 s to 4 min), 0.30 mmol/kg/min (4-8 min) and 0.12 mmol/kg/min (8 min onward) until in situ brain freezing at 15 min. Blood was obtained from a fronto-orbital artery just before the end of the infusion for measurement of the plasma concentrations and 13 C label enrichments of the respective substrates. Substrate infusions were terminated at the appropriate times by immersing the head of the anesthetized mouse in liquid nitrogen.
Preparation of brain and plasma sample for NMR analysis Tissue comprising PFC was dissected from the frozen brain in a microtome maintained at À20°C to avoid post-mortem changes. Metabolites were extracted using HCl/methanol and ethanol as described in Patel et al. (2001) . In brief, frozen brain tissue was ground with 0.1N HCl in methanol (2:1 vol/wt) in a glass homogenizer maintained in a dry-ice/ethanol bath, and homogenized with 60% ice-cold ethanol (6:1 vol/wt). The supernatant was lyophilized and dissolved in phosphate buffer (25 mM Evaluation of metabolic rate of astroglia and neurons Acetate is metabolized mainly in astrocytes, and oxidized therein to label glutamine-C4, which in turn labels glutamate-C4 and GABA-C2 in neurons via glia-to-neuron neurotransmitter cycling (Patel et al. 2010) . The cerebral metabolic rate of acetate oxidation was estimated by the sum of the 13 C label incorporated into different amino acids in the 13 C-edited spectrum during a short time (15 min) infusion of [2- 13 C]acetate as follows (Patel et al. 2010 (Patel et al. , 2017 :
where Gln C4 , Glu C4 , GABA C2 and Glu C3 represent concentrations of 13 C-labeled amino acids from [2-
C 2 ]Glucose is metabolized in both neurons and astroglia, and labels glutamate-C4 in glutamatergic neurons, which is decarboxylated to GABA-C2 in GABAergic neurons. The labeling of glutamine-C4 occurs mainly by trafficking of neurotransmitters (glutamate and GABA) released by neurons, and uptake into astrocytes by glutamate-glutamine and GABA-glutamine cycling. The rate of glucose oxidation by glutamatergic neurons was estimated as follows (Patel et al. 2005) :
where Glu Ci and Asp C3 represent the concentration of 13 C-labeled glutamate and aspartate at the corresponding carbon positions following a 10 min infusion of [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose. The factor 0.82 represents fraction of glutamate localized in the glutamatergic neurons of the cerebral cortex (Tiwari et al. 2013) . The neuronal fraction of aspartate (0.84) was distributed equally (0.42) into glutamatergic and GABAergic neurons (Tiwari et al. 2013) .
The rate of glucose oxidation by GABAergic neurons was obtained using following equation:
where GABA Ci is the concentration of 13 C-labeled GABA at carbon 'i' from [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose. The rate of total (neuronal and astrocytic) glucose oxidation in brain was calculated as follows:
Statistical analysis Statistical analysis was carried out using Graphpad Prism software (Ver 6.01, San Diego, CA, USA). The differences in behavioral phenotype were analyzed using Student's t test prior to treatment with ketamine or saline. Two-way ANOVA analysis was carried out to assess the global effects of treatment in the sucrose preference, SI, immobility time, neurometabolite levels and metabolic rates among different groups post-treatment. An assessment of the normality of data in each group was carried out using the Kolmogorov-Smirnov test prior to ANOVA analysis. The post hoc Tukey honest test was carried out to further identify the statistical significance of difference between groups. Unless specified data are presented as mean AE SEM.
Results
Effect of ketamine on behavior in SD mice
The socially defeated mice showed significant reductions in sucrose preference (SD 64.6 AE 2.0, n = 25; Controls 86.0 AE 1.5, n = 13; p < 0.0001) and in SI (SD 56.9 AE 5.4, n = 25; Controls 148.1 AE 6.7, n = 25; p < 0.0001) before ketamine treatment (Fig. 2a) . The normality assessment using the Kolmogorov-Smirnov test suggested normal distribution of data except for ketamine group mice (p ≤ 0.0064). Two-way analysis of variance indicated there was a significant SD stress 9 ketamine interaction for sucrose preference Post hoc analysis indicated that subanesthetic ketamine administration in SD mice improved sucrose preference over that of saline (SD + Ket 85.6 AE 1.7%, n = 13; SD + NS 65.8 AE 3.6%, n = 12; p < 0.0001), and was not significantly different from controls (Control + NS 86.0 AE 1.7%, n = 5; p > 0.9) (Fig. 2b) . Moreover, SI in SD mice improved significantly (p = 0.0001) following ketamine treatment compared to saline (SD + Ket 151.9 AE 19.2%, n = 13; SD + NS 51.0 AE 6.0%, n = 12), and was not significantly different from normal saline (NS) treated controls (Control + NS 145.2 AE 14.5%, n = 11, p = 0.9917) (Fig. 2b) . Immobility time in SD mice decreased significantly (p < 0.0001) following ketamine treatment (SD + Ket 14.9 AE 5.3 s, n = 7; SD + NS = 71.9 AE 7.8 s; n = 7). Subanesthetic ketamine had no effect (p ≥ 0.53) on sucrose preference, SI or immobility time in control mice.
Effect of ketamine on concentrations of PFC neurometabolites in SD mice
The levels of PFC metabolites were quantified from the unedited ( Control + NS 14.8 AE 0.3 lmol/g, n = 11, p = 0.018) and NAA (SD + NS 8.2 AE 0.8, n = 12; Control + NS 9.0 AE 0.6 lmol/g, n = 11 p = 0.031) in SD mice when compared with saline-treated controls (Table 1) , whereas the levels of other metabolites were unchanged (p ≥ 0.158). Ketamine-treated SD mice had higher levels of glutamate and NAA than saline-treated SD mice, although the differences did not reach statistical significance (p ≥ 0.051). No other effects of ketamine on neurometabolite levels were seen (p > 0.51). C]glycine as a concentration reference. Values are presented as mean AE SD. Glu, glutamate; GABA, c-amino butyric acid; Gln, glutamine; Asp, aspartate; NAA, N-acetyl aspartate; Ino, inositol; Tau, taurine; Cho, choline; Cre, creatine; NS, normal saline; SD, social defeat; Ket, ketamine. mice, and was similar (p ≥ 0.75) to that in NS-treated controls. No effects of ketamine on amino acids labeling were seen (p = 0.79) in control mice.
Effect of ketamine on astroglial metabolic activity in SD mice
Cerebral metabolic rate of acetate oxidation was decreased significantly (p = 0.0016) in SD mice (0.066 AE 0.005 lmol/ g/min) when compared with NS-treated controls (0.094 AE 0.004 lmol/g/min) (Fig. 4) , and this effect was reversed in SD mice by ketamine (0.088 AE 0.005 lmol/g/ min; p = 0.012). No effect of ketamine (p = 0.886) was seen in control mice. These data suggest that astroglial metabolic Sucrose preference was measured by calculating the percentage of the volume of sucrose consumed to the total volume (2% sucrose solution + water). As two control mice were housed in each case, the sucrose preference value reflect the averaged measurements from two animals. SI ratio was determined by taking the percentage of the ratio of time spent by intruder mouse (C57BL/6J) in interaction zone in presence and absence of aggressor mouse (CD1). The helplessness of mice was evaluated by monitoring the time spent by mice in the immobile state. Values represent meanAEstandard error of mean.
activity is significantly improved following ketamine treatment.
Effect of ketamine on neuronal metabolic activity in SD mice
The labeling of plasma glucose following 13 C-glucose infusion was not significantly different (p ≥ 0.138) between the groups (Control + NS 34.7 AE 1.9%, SD + NS 37.9 AE 3.2%, Control + Ket 31.4 AE 1.5%, SD + Ket 34.1 AE 1.3%). There was significant stress 9 ketamine interaction on C-labeled glutamate-C4, GABA-C2 and glutamine-C4 were significantly lower (p ≤ 0.032) in SD mice when compared with NS-treated controls (Table 3 , Fig. 5) . Consequently, the rates of glucose oxidation in glutamatergic (SD + NS 0.226 AE 0.016, n = 5; Control + NS 0.310 AE 0.019 lmol/g/min, n = 5, p = 0.018) and GABAergic neurons (SD + NS 0.042 AE 0.003, n = 5; Control + NS 0.067 AE 0.002 lmol/g/min, n = 5, p = 0.001) were significantly lower in SD mice (Fig. 6) . Moreover, decreased 13 C labeling of glutamine-C4 (p = 0.01) suggests a reduced rate of neurotransmitter cycling in the SD mice (Table 3) .
Subanesthetic ketamine reversed the deficit in (Table 3 ). The metabolic rates of glucose oxidation in glutamatergic neurons (SD + Ket 0.314 AE 0.013, n = 6; SD + NS 0.231 AE 0.019 lmol/g, n = 5, p = 0.02) and GABAergic neurons (SD + Ket 0.064 AE 0.004, n = 6; SD + NS 0.042 AE 0.004 lmol/g, n = 5, p = 0.0018) in SD mice were increased significantly by ketamine, and rates were not significantly different (p > 0.9) from saline-treated control mice (Fig. 6 ).
Discussion
To our knowledge, this is the first study to evaluate the impact of ketamine on metabolic activity of neurons and astrocytes in PFC in a SD mouse model of depression. SD mice exhibited depression-like behaviors, including anhedonia, social avoidance and lengthened immobility times in the FST, consistent with previous findings by Krishnan et al. (2007) . In SD mice, isotopic labeling of PFC amino acids from 13 C-labeled glucose and acetate were reduced, indicating lower rates of neuronal and astroglial metabolic activity and neurotransmitter cycling compared to control mice. Ketamine treatment reversed both the depression-like behaviors, and the neuronal and astroglial metabolic activity measures to control values. ]-NMR spectra were recorded from prefrontal cortex extracts. Ala C3 , alanine-C3; Asp C3 , aspartate-C3; Cre, creatine; Cho, choline; GABA C2 , c-amino butyric acid-C2; Glu C3 , glutamate-C3; Glu C4 , glutamate-C4; Gln C4 , glutamine-C4; Ino, myo-inositol; NAA, N-acetyl aspartate; Tau, taurine.
In this study, glutamate and NAA levels were lower in PFC of SD mice compared to controls, consistent with our previous findings (Veeraiah et al. 2014) , although lower levels of glutamine, taurine and creatine were not observed.
The levels of glutamate and taurine were reported to be reduced in PFC of chronic forced swim stress rats (Li et al. 2008) , and NAA and glutamate were decreased in hippocampus. In contrast, there was no difference in the level of neurometabolites in PFC of chronic unpredictable stress rats . The reduced levels of glutamate and GABA (Hasler et al. 2007) , and NAA and choline (Gruber et al. 2003) have been reported in PFC of depressed subjects. The perturbation in metabolite homeostasis in SD mice is similar to that observed in depressed subjects. NAA is considered to be a measure of neuronal integrity and mitochondrial health (Rigotti et al. 2007 ). Thus, finding of reduced levels of glutamate and NAA together suggests the loss of viability of glutamatergic neurons in the SD mice. Treatment of SD mice with subanesthetic dose of ketamine normalized glutamate and NAA levels to control levels, whereas no effects of ketamine were seen in non-defeated control mice. Glutamate levels in the PFC and hippocampus of physiologically normal rats were lower following an acutely high dose (80 mg/kg) of ketamine, but not after a subanesthetic dose (30 mg/kg) (Chowdhury et al. 2012) . Our finding of no significant change in glutamate level with 10 mg/kg ketamine in normal mice is in good agreement with previous report. ## p < 0.01 when SD + Ket mice were compared with SD + NS. 13 C Concentration of amino acids was calculated from proton-observed carbon-edited NMR spectroscopy of prefrontal cortex extract using glycine as a concentration reference. Values are presented as mean AE SEM. Glu, glutamate; GABA, c-amino butyric acid; Gln, glutamine; NS, normal saline; SD, social defeat; Ket, ketamine. ## p < 0.01 when SD + NS mice were compared with SD + Ket.
13
C Concentration was calculated from proton-observed carbon-edited NMR spectroscopy of prefrontal cortex extract using glycine as a concentration reference. Values are presented as mean AE SD. Glu, glutamate; GABA, c-amino butyric acid; Gln, glutamine; Asp, aspartate; NS, normal saline; SD, social defeat; Ket, ketamine.
The expression of astroglial glutamate transporter 1 (GLT1) (or excitatory amino acid transporter 2 in humans), is reduced in the hippocampus of rats subjected to chronic unpredictable mild stress (Zhu et al. 2017) , and hippocampus and occipital cortex following learned helplessness (Zink et al. 2010) , as well as in PFC of SD mice (Veeraiah et al. 2014) . The reduced expression of GLT1 suggests a decreased in glutamate uptake capacity in astroglia, potentially compromising neurotransmitter cycling in depression. Reduced glutamate-glutamine cycling has been reported from 13 C-labeled acetate in rats subjected to chronic unpredictable stress, which is reversed by riluzole , a treatment known to increase GLT1 expression and astroglial glutamate uptake. Recently, 13 C NMR spectroscopy was used to assess neuronal energetics in MDD in humans (Abdallah et al. 2014) , reporting that glucose oxidation in the TCA cycle of glutamatergic neurons was decreased nearly 26% in occipital cortex of depressed subjects relative to healthy controls, although glutamateglutamine cycling was unaltered. We previously reported that 13 C labeling in PFC amino acids from [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose was reduced in SD mice, indicating decreased rates of neuronal TCA cycle in the depressed mice (Veeraiah et al. 2014) . Consistent with these findings, the current results show reduced glucose oxidation in glutamatergic (À27%) and GABAergic neurons (À37%), and reduced glutamateglutamine neurotransmitter cycling in the SD mice.
There are very few studies evaluating the effects of depression on astroglial metabolic activity. Using [2-
13 C]acetate infusion in rats subjected to chronic unpredictable stress, 13 C labeling of glutamate, GABA and glutamine was reported to be reduced . Moreover, the expression of the glial fibrillary acidic protein was reduced in rats subjected to unpredictable stress suggesting compromised astroglial function in stressed animals. In addition, reduced glial cell density is seen in the rostral orbitofrontal C-labeled metabolites. Ala C3 , alanine-C3; Asp C3 , aspartate-C3; Cre, creatine; Cho, choline; GABA C2 , c-amino butyric acid-C2; Glu C3 , glutamate-C3; Glu C4 , glutamate-C4; Gln C4 , glutamine-C4; Ino, myo-inositol; NAA, Nacetyl aspartate; Tau, taurine. CMR Glc(Ox) was calculated using eqns 3-5. The symbols represent value from individual animals and data represented as mean AE standard error of mean.
region of post-mortem tissue from depressed subjects (Ongur et al. 1998) . Stereological analysis has shown that the volume of glial fibrillary acidic protein positive astrocytes is significantly lower in the hippocampus of Flinders Sensitive Line rats, which spontaneously develop a depression-like phenotype (Ardalan et al. 2017) . In this study, labeling in glutamate-C4 (À27%) and glutamine-C4 (À25%) from [2- 13 C]acetate in PFC of SD mice was reduced as compared with controls. Quantitatively, the reduced labeling of PFC amino acids corresponds to a~30% reduction in acetate oxidation in the SD mice. Moreover, the reduced labeling of glutamate-C4 from [2- 13 C]acetate suggests decreased glutamate-glutamine neurotransmitter cycling in the SD mice.
Although ketamine has been an important molecule exhibiting antidepressant activity, its mechanism of action is poorly understood. A recent 13 C NMR study in rats suggested glutamate surge in the PFC in normal rats following subanesthetic dose of ketamine (Chowdhury et al. 2017) . Moreover, glutamine labeling was shown to be increased within the first 8 min, and the effect was sustained until 18 min after ketamine injection. The ketamine effect dissipated over the course of 1 h, and no difference in neurotransmitter cycling was found at 24 h, a time point when the antidepressant-like activity of ketamine had been assessed. Similar effects were seen with another NMDA receptor antagonist, Ro-25-6981. Together, the results suggest that an early surge in medial PFC glutamate metabolism might be involved in the subsequent antidepressant effects. A very recent study has indicated a time-dependent alteration in levels of hippocampal metabolites involved in the glycolytic and TCA cycle pathways starting at 2 h, and lasted till 72 h after 3 mg/kg ketamine treatment in normal mice (Weckmann et al. 2014) . Our analysis, which was conducted 48 h post-ketamine treatment, indicates neuronal and astroglial metabolic activity is restored in SD mice following acute ketamine treatment. However, there was no significant change (p ≥ 0.284) in the level of 13 C-labeled amino acids in control mice following 48 h of ketamine versus saline administration, which is consistent with the previous study (Chowdhury et al. 2017) in which rats were measured at 24 h following a 10 mg/kg ketamine dose. However, SD mice showed significantly increased 13 C labeling in glutamate-C4 (44%, p = 0.001), GABA-C2 (75%, p = 0.002) and glutamine-C4 (67%, p = 0.0018) following ketamine treatment. Quantitatively, rates of glucose oxidation of glutamatergic (0.310 AE 0.019 vs. 0.226 AE 0.016 lmol/g/ min) and GABAergic (0.067 AE 0.002 vs. 0.042 AE 0.003 lmol/g/min) neurons were increased in SD mice treated with ketamine compared to NS-treated SD mice. The ketamine-induced increase in glutamatergic neuronal activity in the SD mice is supported by increased expression of excitatory amino acid transporter 2 with ketamine in the hippocampus of CUMS rats (Zhu et al. 2017) . These data suggest that antidepressant effect of ketamine lies in its ability to increase neuronal activity and neurotransmitter cycling in depressed mice.
Neuronal-astroglial trafficking plays an important role in the normal functioning of neural circuitry. Astroglia are important for the supply of glutamine, a precursor to neurons for the replenishment of neurotransmitters, glutamate and GABA (Patel et al. 2001) . The data from this study indicate that astroglial metabolic activity is reduced in PFC of SD mice. A significant increase in volume and length of astrocytic branches has been reported in depressed rats 1 day after a single injection of ketamine (Ardalan et al. 2017) . However, little information is presently available on ketamine's effect on astroglial metabolic activity. Our results indicate that glutamine-C4 and glutamate-C4 labeling from [2- 13 C]acetate is increased in ketamine-treated SD mice, relating to an increase in acetate oxidation in the astroglial compartment. The increased labeling of glutamate in PFC points toward improved glutamate-glutamine neurotransmitter cycling in the SD mice treated with ketamine. Hence, ketamine has beneficial impact on astroglial and glutamatergic neuronal metabolic activity and glutamate-glutamine cycling in the PFC of mice subjected to SD stress.
A correlation analysis between the assessed behavioral measures and metabolic rates was carried out by including data from all mouse groups. As two control mice were housed in each case, the measured sucrose preference was averaged of two control mice. Therefore, average of metabolic rates of two control mice were used for correlation involving metabolic rates and sucrose preference. Glucose oxidation rates associated with glutamatergic and GABAergic neurons correlated positively with sucrose preference (R 2 = 0.55), as well as with SI but to a lesser degree ( Fig. 7a  and b) . The rate of acetate oxidation, which is a measure of astroglial metabolic activity, correlated (R 2 = 0.35) positively with sucrose preference (Fig. 7c) . In contrast, astroglial metabolic activity correlated (R 2 = 0.329) negatively with immobility of the animals in the Forced Swim Test (Fig. 7c) .
There is a potential limitation in the use of trapping of isotopic labels into different neurometabolites for estimation of metabolic rates using eqns 3-5. This approach does not account for the flow of label from glutamate-C4 into glutamine-C4 via neurotransmitter cycling. Moreover, 13 C label lost as CO 2, and shuttled into lactate-C3 and alanine-C3 were not accounted. Hence, the cerebral metabolic rates of glucose oxidation by glutamatergic and GABAergic neurons will be underestimated. However, it may be argued that underestimates in metabolic rates would be of similar degrees in different groups. Hence, the relative values, and direction of the changes in the respective metabolic rates would remain the same, and will not have much impact on the conclusion of the study. A more accurate measure of cerebral metabolic rates of glucose and acetate oxidation by different neural cell types could be obtained by metabolic modeling of the (Patel et al. 2010) as long as metabolic steady state conditions prevail during the length of measurements, such as that occurring in the control and SD mice 48 h after ketamine administration.
Conclusion
In summary, this study demonstrates that chronic SD stress, which induces a depression-like phenotype such as anhedonia, social avoidance and helplessness, results in impaired metabolic activity in glutamatergic neurons, GABAergic neurons and astroglia, and glutamate-glutamine neurotransmitter cycling. Subanesthetic ketamine abolished the behavioral effects, and restored neural metabolic activity and excitatory neurotransmitter cycling to control levels in socially defeated mice. C]acetate, respectively. As in case of control mice, the measured values reflect the sucrose preference of two animals, the average metabolic rates of these mice were used for the correlation analysis involving metabolic rates and sucrose preference.
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